Patents by Inventor Stephen McAndrew

Stephen McAndrew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5980896
    Abstract: The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity.
    Type: Grant
    Filed: June 14, 1993
    Date of Patent: November 9, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ingegerd Hellstrom, Karl Erik Hellstrom, Kim Folger Bruce, George J. Schreiber, Clay Siegall, Stephen McAndrew
  • Patent number: 5840854
    Abstract: The present invention provides internalizing ligands (i.e., BR110 ligands) which specifically recognize and bind the BR110 antigen. After binding the antigen, the ligand and antigen form a complex. As a complex, the antigen can be detected using well known and developed methods and commercial systems.
    Type: Grant
    Filed: October 7, 1996
    Date of Patent: November 24, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Karl Erik Hellstrom, Ingegerd Hellstrom, Ursula Garrigues, Stephen McAndrew, Hans Marquardt